$CNMD

CONMED Corp

CONMED is a medical technology company that provides devices and equipment for surgical procedures. Surgeons and other healthcare professionals use its products in orthopedics, general surgery, gynecology, thoracic surgery and gastroenterology. Its two main product lines are orthopedic surgery and general surgery. Orthopedic products include implants, powered instruments, fluid management and visualization systems, and bone power tools. General surgery products include insufflation systems, smoke evacuation devices, electrosurgical and endomechanical instruments, endoscopic products and patient monitoring equipment. CONMED sells through direct sales, medical specialty distributors, local country dealers and sales subsidiaries. Its products are sold in over 100 countries, and it distributes them from three primary manufacturing locations. The company is headquartered in Largo, Florida.

AlphAI earnings readThird Quarter 2026 · OCT 28CONMED Corporation Reports Third Quarter 2026 Financial Results; Updates Full Year 2026 GuidanceVerdict: mixed

Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.

No enriched coverage for $CNMD in the last 7 days.

No SEC Form 4 filings for $CNMD in the last 30 days.

See all $CNMD insider activity →

CNMD Q3 deep dive: stable revenue, margin improvement, and focus on core growth platforms

CONMED reported Q3 revenue of $335.6M, matching estimates, with adjusted EPS of $1.04, beating estimates by 3.7%. Adjusted EBITDA was $67.88M, a 2.9% beat. The company reconfirmed revenue guidance of $1.36B and raised adjusted EPS guidance to $4.58. Operating margin improved to 11.1%. International sales and AirSeal platform growth drove performance, while U.S. orthopedic sales declined.

CNMD sentiment & insider activity

Recent CNMD coverage spans earnings, financial news and market movers.

What's driving CNMD

AlphAI scores every news story that mentions CNMD with an AI model for sentiment and relevance, and aggregates insider trades from CONMED Corp's SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $CNMD

Score

CNMD Q3 deep dive: stable revenue, margin improvement, and focus on core growth platforms

CONMED reported Q3 revenue of $335.6M, matching estimates, with adjusted EPS of $1.04, beating estimates by 3.7%. Adjusted EBITDA was $67.88M, a 2.9% beat. The company reconfirmed revenue guidance of $1.36B and raised adjusted EPS guidance to $4.58. Operating margin improved to 11.1%. International sales and AirSeal platform growth drove performance, while U.S. orthopedic sales declined.

CNMD Jumps 16% in a Month as Investors Assess Whether It Can Last

CONMED (CNMD) shares rose 16% over the past month as investors weighed improved profitability and a raised 2026 earnings outlook. Q2 revenue was $343.5M (+0.3% YoY); gross margin rose to 57.5%. Adjusted EBITDA was $78.1M (22.7% margin). 2026 EPS guidance increased to $4.48-$4.60, but operating cash flow and free cash flow guidance were weaker.

Related tickers